CD3-positive plasmablastic B-cell neoplasms

A diagnostic pitfall

Zenggang Pan, Mingyi Chen, Qianyun Zhang, Endi Wang, Liqun Yin, Youyuan Xu, Qin Huang, Youzhong Yuan, Xiaohui Zhang, Gang Zheng, Ji Yuan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rare B-cell neoplasms with plasmablastic differentiation may aberrantly express CD3 by immunohistochemical staining, which places a great challenge for diagnosis. We here studied 17 cases of CD3+ plasmablastic B-cell neoplasms, including 12 plasmablastic lymphomas and 5 plasmablastic plasma cell myelomas. All 17 cases occurred in the extranodal sites with a male predominance (13/17). Four cases were initially misinterpreted by outside institutions, among which three were diagnosed as €peripheral T-cell lymphoma, not otherwise specified' and one was classified as € poorly differentiated neuroendocrine carcinoma'. The plasmablastic cells were present in all 17 cases diffusely or in a subset of tumor cells. CD3 expression was mostly diffuse (12/17) and moderate to strong (11/16) with a cytoplasmic staining pattern (14/16). Other T-cell markers were nearly absent, including CD2 (0/10), CD4 (1/13), CD5 (0/14), CD7 (0/11), and CD8 (0/13). CD138 was positive in all 17 cases and CD79a was variably positive in 8 of 14 cases. Only one case had immunoreactivity to CD20 (1/17) and PAX5 (1/12). CD56 expression and EBV infection were detected in 8/15 and 6/17, respectively. No HHV8 infection was noted in all 11 cases tested. Most cases (11/13) revealed either kappa or lambda light chain restriction. Of the nine cases studied, six had clonal IGH rearrangements but no clonal TRG rearrangements. Our study further emphasizes that the accurate classification of CD3+ plasmablastic neoplasms requires thorough morphologic examination, incorporation of more B-cell and T-cell markers in addition to CD3 and CD20, frequent addition of CD138 staining, and utilization of necessary molecular and genetic studies.

Original languageEnglish (US)
Pages (from-to)718-731
Number of pages14
JournalModern Pathology
Volume31
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

B-Lymphocytes
Staining and Labeling
Neoplasms
Peripheral T-Cell Lymphoma
T-Lymphocytes
Neuroendocrine Carcinoma
Epstein-Barr Virus Infections
Multiple Myeloma
Molecular Biology
Light
Infection

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

CD3-positive plasmablastic B-cell neoplasms : A diagnostic pitfall. / Pan, Zenggang; Chen, Mingyi; Zhang, Qianyun; Wang, Endi; Yin, Liqun; Xu, Youyuan; Huang, Qin; Yuan, Youzhong; Zhang, Xiaohui; Zheng, Gang; Yuan, Ji.

In: Modern Pathology, Vol. 31, No. 5, 01.05.2018, p. 718-731.

Research output: Contribution to journalArticle

Pan, Z, Chen, M, Zhang, Q, Wang, E, Yin, L, Xu, Y, Huang, Q, Yuan, Y, Zhang, X, Zheng, G & Yuan, J 2018, 'CD3-positive plasmablastic B-cell neoplasms: A diagnostic pitfall', Modern Pathology, vol. 31, no. 5, pp. 718-731. https://doi.org/10.1038/modpathol.2017.177
Pan, Zenggang ; Chen, Mingyi ; Zhang, Qianyun ; Wang, Endi ; Yin, Liqun ; Xu, Youyuan ; Huang, Qin ; Yuan, Youzhong ; Zhang, Xiaohui ; Zheng, Gang ; Yuan, Ji. / CD3-positive plasmablastic B-cell neoplasms : A diagnostic pitfall. In: Modern Pathology. 2018 ; Vol. 31, No. 5. pp. 718-731.
@article{a9dec017e50d4e53a07da2ef50ae2cd4,
title = "CD3-positive plasmablastic B-cell neoplasms: A diagnostic pitfall",
abstract = "Rare B-cell neoplasms with plasmablastic differentiation may aberrantly express CD3 by immunohistochemical staining, which places a great challenge for diagnosis. We here studied 17 cases of CD3+ plasmablastic B-cell neoplasms, including 12 plasmablastic lymphomas and 5 plasmablastic plasma cell myelomas. All 17 cases occurred in the extranodal sites with a male predominance (13/17). Four cases were initially misinterpreted by outside institutions, among which three were diagnosed as €peripheral T-cell lymphoma, not otherwise specified' and one was classified as € poorly differentiated neuroendocrine carcinoma'. The plasmablastic cells were present in all 17 cases diffusely or in a subset of tumor cells. CD3 expression was mostly diffuse (12/17) and moderate to strong (11/16) with a cytoplasmic staining pattern (14/16). Other T-cell markers were nearly absent, including CD2 (0/10), CD4 (1/13), CD5 (0/14), CD7 (0/11), and CD8 (0/13). CD138 was positive in all 17 cases and CD79a was variably positive in 8 of 14 cases. Only one case had immunoreactivity to CD20 (1/17) and PAX5 (1/12). CD56 expression and EBV infection were detected in 8/15 and 6/17, respectively. No HHV8 infection was noted in all 11 cases tested. Most cases (11/13) revealed either kappa or lambda light chain restriction. Of the nine cases studied, six had clonal IGH rearrangements but no clonal TRG rearrangements. Our study further emphasizes that the accurate classification of CD3+ plasmablastic neoplasms requires thorough morphologic examination, incorporation of more B-cell and T-cell markers in addition to CD3 and CD20, frequent addition of CD138 staining, and utilization of necessary molecular and genetic studies.",
author = "Zenggang Pan and Mingyi Chen and Qianyun Zhang and Endi Wang and Liqun Yin and Youyuan Xu and Qin Huang and Youzhong Yuan and Xiaohui Zhang and Gang Zheng and Ji Yuan",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/modpathol.2017.177",
language = "English (US)",
volume = "31",
pages = "718--731",
journal = "Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - CD3-positive plasmablastic B-cell neoplasms

T2 - A diagnostic pitfall

AU - Pan, Zenggang

AU - Chen, Mingyi

AU - Zhang, Qianyun

AU - Wang, Endi

AU - Yin, Liqun

AU - Xu, Youyuan

AU - Huang, Qin

AU - Yuan, Youzhong

AU - Zhang, Xiaohui

AU - Zheng, Gang

AU - Yuan, Ji

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Rare B-cell neoplasms with plasmablastic differentiation may aberrantly express CD3 by immunohistochemical staining, which places a great challenge for diagnosis. We here studied 17 cases of CD3+ plasmablastic B-cell neoplasms, including 12 plasmablastic lymphomas and 5 plasmablastic plasma cell myelomas. All 17 cases occurred in the extranodal sites with a male predominance (13/17). Four cases were initially misinterpreted by outside institutions, among which three were diagnosed as €peripheral T-cell lymphoma, not otherwise specified' and one was classified as € poorly differentiated neuroendocrine carcinoma'. The plasmablastic cells were present in all 17 cases diffusely or in a subset of tumor cells. CD3 expression was mostly diffuse (12/17) and moderate to strong (11/16) with a cytoplasmic staining pattern (14/16). Other T-cell markers were nearly absent, including CD2 (0/10), CD4 (1/13), CD5 (0/14), CD7 (0/11), and CD8 (0/13). CD138 was positive in all 17 cases and CD79a was variably positive in 8 of 14 cases. Only one case had immunoreactivity to CD20 (1/17) and PAX5 (1/12). CD56 expression and EBV infection were detected in 8/15 and 6/17, respectively. No HHV8 infection was noted in all 11 cases tested. Most cases (11/13) revealed either kappa or lambda light chain restriction. Of the nine cases studied, six had clonal IGH rearrangements but no clonal TRG rearrangements. Our study further emphasizes that the accurate classification of CD3+ plasmablastic neoplasms requires thorough morphologic examination, incorporation of more B-cell and T-cell markers in addition to CD3 and CD20, frequent addition of CD138 staining, and utilization of necessary molecular and genetic studies.

AB - Rare B-cell neoplasms with plasmablastic differentiation may aberrantly express CD3 by immunohistochemical staining, which places a great challenge for diagnosis. We here studied 17 cases of CD3+ plasmablastic B-cell neoplasms, including 12 plasmablastic lymphomas and 5 plasmablastic plasma cell myelomas. All 17 cases occurred in the extranodal sites with a male predominance (13/17). Four cases were initially misinterpreted by outside institutions, among which three were diagnosed as €peripheral T-cell lymphoma, not otherwise specified' and one was classified as € poorly differentiated neuroendocrine carcinoma'. The plasmablastic cells were present in all 17 cases diffusely or in a subset of tumor cells. CD3 expression was mostly diffuse (12/17) and moderate to strong (11/16) with a cytoplasmic staining pattern (14/16). Other T-cell markers were nearly absent, including CD2 (0/10), CD4 (1/13), CD5 (0/14), CD7 (0/11), and CD8 (0/13). CD138 was positive in all 17 cases and CD79a was variably positive in 8 of 14 cases. Only one case had immunoreactivity to CD20 (1/17) and PAX5 (1/12). CD56 expression and EBV infection were detected in 8/15 and 6/17, respectively. No HHV8 infection was noted in all 11 cases tested. Most cases (11/13) revealed either kappa or lambda light chain restriction. Of the nine cases studied, six had clonal IGH rearrangements but no clonal TRG rearrangements. Our study further emphasizes that the accurate classification of CD3+ plasmablastic neoplasms requires thorough morphologic examination, incorporation of more B-cell and T-cell markers in addition to CD3 and CD20, frequent addition of CD138 staining, and utilization of necessary molecular and genetic studies.

UR - http://www.scopus.com/inward/record.url?scp=85046831873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046831873&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2017.177

DO - 10.1038/modpathol.2017.177

M3 - Article

VL - 31

SP - 718

EP - 731

JO - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

JF - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

SN - 0893-3952

IS - 5

ER -